ASCAHIFA and Biosfer Teslab on Familial Hypercholesterolemia Day

ASCAHIFA and Biosfer Teslab join forces to advance the diagnosis of familial hypercholesterolemia with Liposcale®

On September 24, we celebrate Familial Hypercholesterolemia (FH) Day, a hereditary genetic condition that causes very high levels of LDL cholesterol from birth and greatly increases the risk of developing premature cardiovascular disease.

It is estimated that FH affects 1 in 250 people, which translates into more than 180,000 cases in Spain. However, fewer than 20% are diagnosed, meaning that thousands of people are unaware they have the condition and are not receiving appropriate treatment. Early identification is essential to prevent severe cardiovascular complications, since current therapies can significantly reduce the risk of heart attack and other related conditions.

What is ASCAHIFA?

ASCAHIFA (Associació Catalana d’Hipercolesterolèmia Familiar) is a non-profit organization that brings together patients and families affected by FH in Catalonia and the Balearic Islands. Its mission is to support families, promote early diagnosis, provide reliable scientific information, and collaborate with healthcare professionals and authorities to improve patient care.

Biosfer Teslab and Liposcale®

In this context, ASCAHIFA is strengthening its commitment to patients through a collaboration with Biosfer Teslab, bringing the Liposcale® test closer as an innovative tool to improve the detection and monitoring of familial hypercholesterolemia.

Liposcale® is an advanced test based on NMR spectroscopy that provides a detailed profile of blood lipoprotein particles. Thanks to this technology, cardiovascular risk can be characterized with greater precision than conventional analyses, enabling a more personalized clinical approach.

Objectives of the collaboration

  1. Promote the use of Liposcale® among patients and healthcare professionals dealing with familial hypercholesterolemia.
  2. Generate clinical evidence to support the utility of the test in medical practice.
  3. Raise awareness and improve understanding of the disease across society.
  •  

A partnership with real impact

“With Liposcale® we take a step forward in the diagnosis and management of familial hypercholesterolemia. We want every patient to have access to tools that truly make a difference in their cardiovascular health.”

ASCAHIFA and Biosfer Teslab share the same commitment: that no person with familial hypercholesterolemia should remain undiagnosed or untreated. This International Day serves as a reminder that science, technology, and patient associations can move forward hand in hand to transform the lives of thousands of families.